Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.
Eli Lilly expects to beat profit forecasts on obesity drug demand
The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to sharp sell-offs in its shares.
Eli Lilly’s Annual Profit View in Line After Recent Misses
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on sales in recent quarters.
Lilly forecasts 2025 profit growth after recent weight-loss drug worries
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after another quarter of sales miss for its popular diabetes and weight-loss treatments.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
FierceBiotech23h
Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
STAT3h
Lilly expands GLP-1 research to hypertension, neuro conditions
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
FierceBiotech1d
UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...
BioSpace5h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...